Najnowsze artykuły:
Biogen and Ionis Pharmaceuticals have announced study results from CHERISH, the phase 3 study evaluating SPINRAZA (nusinersen) for the treatment of individuals with later-onset spinal muscular atrophy ...
Treatment with onasemnogene abeparvovec gene therapy for spinal muscular atrophy (SMA) type 1 was associated with less need for nutritional support or nighttime ventilation compared to recommended ...
Biogen Inc.: FDA Approves New High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA ...
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved ...
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved ...